Helsinn Group pinpoints innovative pharmaceutical products and medical devices in the early development phase and in-licenses the candidate by acquiring the world-wide rights.

Through the internal financing and management of the product’s (either an originator’s molecule or device) development, Helsinn secures it a valuable international market position.

The Group provides technological and scientific infrastructures for pre-clinical, clinical and industrial development, according to the highest scientific, quality and ethical standards, and in full compliance with FDA and EU requirements.

As soon as the development phase is completed, with the attainment of the registration in US, Europe, Japan and other markets, Helsinn’s product is ready for world-wide distribution and sale through an established network of international partners supported by the Group’s logistic infrastructure and post-marketing services.

Helsinn has a large product development capability ranging from early optimization phase, preclinical phase and throughout all phases of clinical development and a proven expertise in oncology and cancer supportive care, pain and inflammation, and gastrointestinal therapeutic areas.